United States v. Kyle Hebert ( 2019 )


Menu:
  •      Case: 18-30321      Document: 00514888158         Page: 1    Date Filed: 03/26/2019
    IN THE UNITED STATES COURT OF APPEALS
    FOR THE FIFTH CIRCUIT
    United States Court of Appeals
    Fifth Circuit
    No. 18-30321
    FILED
    March 26, 2019
    Summary Calendar
    Lyle W. Cayce
    Clerk
    UNITED STATES OF AMERICA,
    Plaintiff–Appellee
    v.
    KYLE JAMES HEBERT,
    Defendant–Appellant
    Appeal from the United States District Court
    for the Western District of Louisiana
    USDC No. 2:17-CR-39-1
    Before DENNIS, CLEMENT, and OWEN, Circuit Judges.
    PER CURIAM: *
    Kyle James Hebert appeals his convictions on one count of conspiring
    with Kohll’s Pharmacy & Homecare, Inc., doing business as Essential
    Pharmacy Compounding, to deliver in interstate commerce an adulterated and
    misbranded prescription animal drug with the intent to defraud federal and
    state regulatory agencies including the federal Food and Drug Administration
    (FDA), 
    18 U.S.C. § 371
    ; two counts of receiving an adulterated or misbranded
    * Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not
    be published and is not precedent except under the limited circumstances set forth in 5TH
    CIR. R. 47.5.4.
    Case: 18-30321    Document: 00514888158      Page: 2   Date Filed: 03/26/2019
    No. 18-30321
    drug in interstate commerce and delivering or offering to deliver the drug with
    the intent to defraud or mislead, 
    21 U.S.C. §§ 331
    (c), 333(a)(2); and one count
    of affecting the label of a drug held for sale and misbranding a drug with the
    intent to defraud and mislead while holding the drug for sale, 
    21 U.S.C. §§ 331
    (k), 333(a)(2). The district court sentenced Hebert to 15 months in prison
    and 3 years of supervised release on each of the four counts, with the prison
    terms to run concurrently to each other and the supervised release terms to
    run concurrently to each other.
    Whether the district court erred in disallowing Hebert’s three character
    witnesses to testify that Hebert would never knowingly endanger racehorses
    or others on the racetrack, Hebert fails to show a reasonable probability, in
    light of the extensive evidence in this matter, that he would have avoided
    conviction had the district court ruled otherwise. See United States v. De Leon,
    
    728 F.3d 500
    , 505 (5th Cir. 2013).
    Hebert also fails to show that, even under de novo review, the district
    court erred in instructing the jury. See United States v. Copeland, 
    820 F.3d 809
    , 811 (5th Cir. 2016). The district court presented, in the charge as a whole,
    a substantially correct statement of the law, and the instructions did not
    impair Hebert’s ability to defend himself. See United States v. Peterson, 
    101 F.3d 375
    , 381 (5th Cir. 1996). The finding of intent for purposes of § 333 as to
    each count charged necessarily required the conclusion that Hebert acted
    willfully. See United States v. Arlen, 
    947 F.2d 139
    , 143 (5th Cir. 1991).
    Hebert’s challenge to the district court’s denial of his motion to dismiss
    the indictment is likewise unavailing even under de novo review. See United
    States v. Gonzalez, 
    792 F.3d 534
    , 537 (5th Cir. 2015). As the district court
    concluded, this court has focused, in defining a “new drug” under 
    21 U.S.C. § 321
    (p), and a “new animal drug” under 
    21 U.S.C. § 321
    (v), on a “drug’s
    2
    Case: 18-30321     Document: 00514888158     Page: 3   Date Filed: 03/26/2019
    No. 18-30321
    composition and use rather than on the process by which it was created.” Med.
    Ctr. Pharmacy v. Mukasey, 
    536 F.3d 383
    , 395, 407 (5th Cir. 2008); see Leocal
    v. Ashcroft, 
    543 U.S. 1
    , 12 n.8 (2004). Because the FDA had not approved
    dermorphin as safe and effective for use for horses, the drug was, by definition,
    a “new animal drug.” See 
    21 U.S.C. § 321
    (v); United States v. Fontenot, 
    665 F.3d 640
    , 644 (5th Cir. 2011). Because this new animal drug lacked FDA
    approval, it was, also by definition, “adulterated.” 
    21 U.S.C. § 351
    (a)(5); United
    States v. An Article of Drug Consisting of 4,680 Pails, More or Less, Each Pail
    Containing 60 Packets, Etc., 
    725 F.2d 976
    , 980-81 (5th Cir. 1984). The district
    court properly denied the motion to dismiss the indictment for failure to allege
    an offense. See Gonzalez, 792 F.3d at 537.
    The judgment of the district court is AFFIRMED.
    3